Burzynski Research Institute, Inc. (BZYR)
Burzynski Research Institute, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $657,242. On trailing twelve-month figures it carries a trailing P/E of -0.52, a net margin of 0.0%. Its beta of 0.41 implies it has historically moved less than the broad market.
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
Burzynski Research Institute, Inc. is most often compared with the following Healthcare names: